Janux Therapeutics, Inc. (JANX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Janux Therapeutics, Inc. (JANX) is down 0.1% since the beginning of the year. At $14 per share, JANX is trading 61.0% below its 52-week high of $35.

Janux Therapeutics, Inc. (JANX) has returned -0.14% so far this year and -45.81% over the past 12 months.

Based on dividend-adjusted daily data since Jun 11, 2021, JANX's average daily return is +0.18%, while the average monthly return is +6.57%. At this rate, an investment would double in approximately 0.9 years.

Historically, 48% of months were positive and 52% were negative. The best month was Feb 2024 with a return of +465.2%, while the worst month was Dec 2025 at -59.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 3 months.

On a daily basis, JANX closed higher 48% of trading days. The best single day was Feb 27, 2024 with a return of +229.5%, while the worst single day was Dec 2, 2025 at -53.3%.

Janux Therapeutics, Inc. has an annualized alpha of 27.62%, beta of 1.50, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since June 14, 2021.

• This stock participated in 202.32% of S&P 500 Index downside but only 152.50% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

JANX ranks 17 for risk / return — in the bottom 17% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Janux Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Janux Therapeutics, Inc. was 83.14%, occurring on Nov 9, 2023. Recovery took 73 trading sessions.

The current Janux Therapeutics, Inc. drawdown is 79.38%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Janux Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Janux Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.